Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.

Manlay, Luc; Boschetti, Gilles; Pereira, Bruno; Flourié, Bernard; Dapoigny, Michel; Reymond, Maud; Sollelis, Elisa; Gay, Claire; Boube, Mathilde; Buisson, Anthony; Nancey, Stéphane

Manlay, Luc; Boschetti, Gilles; Pereira, Bruno; Flourié, Bernard; Dapoigny, Michel; Reymond, Maud; Sollelis, Elisa; Gay, Claire; Boube, Mathilde; Buisson, Anthony; Nancey, Stéphane.

Afiliação

Manlay L; Université Clermont Auvergne, Inserm, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Clermont-Ferrand, France.
Boschetti G; Department of Gastroenterology, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre Bénite, and INSERM U1111 - CIRI, Lyon, France.
Pereira B; Université Clermont Auvergne, CHU Clermont-Ferrand, DRCI, Unité de Biostatistiques, Clermont-Ferrand, France.
Flourié B; Department of Gastroenterology, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre Bénite, and INSERM U1111 - CIRI, Lyon, France.
Dapoigny M; Université Clermont Auvergne, Inserm, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Clermont-Ferrand, France.
Reymond M; Université Clermont Auvergne, Inserm, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Clermont-Ferrand, France.
Sollelis E; Université Clermont Auvergne, Inserm, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Clermont-Ferrand, France.
Gay C; Department of Gastroenterology, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre Bénite, and INSERM U1111 - CIRI, Lyon, France.
Boube M; Université Clermont Auvergne, Inserm, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Clermont-Ferrand, France.
Buisson A; Université Clermont Auvergne, Inserm, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Clermont-Ferrand, France.
Nancey S; Inserm U1071, M2iSH, USC-INRA 2018, Université Clermont Auvergne, Clermont-Ferrand, France.

Aliment Pharmacol Ther ; 53(12): 1289-1299, 2021 06.

Article em En | MEDLINE | ID: mdl-33909920

Assuntos

Doença de Crohn; Ustekinumab; Adulto; Anticorpos Monoclonais Humanizados/uso terapêutico; Doença de Crohn/tratamento farmacológico; Humanos; Resultado do Tratamento; Inibidores do Fator de Necrose Tumoral; Ustekinumab/uso terapêutico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Crohn / Ustekinumab Tipo de estudo: Prognostic_studies Limite: Adult / Humans Idioma: En Revista: Aliment Pharmacol Ther Assunto da revista: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google